You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab

[Breast Disease, 38(2) 2019, 57–65, DOI 10.3233/BD-180350]

https://content.iospress.com/articles/breast-disease/bd180350

On page 61, Table 2, in the Tz+ group, the average number of immunoreactive CD8 cells in the intratumoral (I) compartment, previously reported as 17.3, has now been revised as 1.73.

On page 62, in Table 2 (continued), within the CD8/Fox-P3 column, the absence of Fox-P3-positive cells, previously reported as “0”, has now been revised as “−”. In addition, in the Tz+ group, in case 6, the number of CD8/Fox-P3-positive cells in the adjacent (A) and distal (D) stromal compartments, previously reported as 1.2 and 6.8, respectively, has now been revised as 6.8 and 1.1, respectively. In the Tz group, in case 13, the number of CD8/Fox-P3-positive cells in the D compartment, previously reported as 1, has now been revised as 6.6. In the Tz+ group, the average CD8/Fox-P3-positive cells in the I, A, and D compartments, previously reported as 0.3, 6.2, and 5.3, respectively, has been revised as 3, 11, and 10.6, respectively. In the Tz group, the average CD8/Fox-P3-positive cells in the A and D compartment, previously reported as 4 and 1.3, respectively, has now been revised as 30.5 and 12.6, respectively.

On page 63, CD4 and CD8 in graph [b] and Fox-P3 and in graph [b and c] of Figure 2 have been revised. Furthermore, the statistical test mentioned at the lower right end of Figure 2, previously reported as Welch’s t-test, has now been revised as Mann–Whitney U test.

The revised Table 2 (Tz+ and Tz group, CD8 and CD8/Fox-P3) is shown below:

Table 2

Expression of CD8 and CD8/Fox-P3-positive cells in each compartment

Tz+ groupCD8CD8/Fox-P3
CaseIADIAD
13.439.263.6
20.686.423.2
32.824.618
41.21.810.8
50.41.420.8
60.2649.46.81.1
70.230.610.4
82.239.8125.510.8
903710.2
10253.815.22.513.512.7
11210621.815.136.3
127.2230.65213.1
131.219.813.8411.5
14019.81.87.19
152.653.61129.8
Average1.735215.83 1110.6

Tz groupCD8CD8/Fox-P3
CaseIADI AD

11.4349.8
20.23.612.2
30.215.216.4
40.613.22.6
52.612.410.4
60.20.82.4
70.47.60.4
80.49.20.446
906.67.418.5
101.220.211.4
111.210.28.2
1200.20.2
130.6310.6156.6
141.218.611.8
Average0.711.17.430.512.6

The revised Fig. 2 is shown below:

Fig. 2.

Number of CD4-, CD8-, and Fox-P3-positive cells in the three different tissue compartments, (a) adjacent lesion, (b) distant lesion, and (c) intratumor lesion, with or without trastuzumab therapy.

Number of CD4-, CD8-, and Fox-P3-positive cells in the three different tissue compartments, (a) adjacent lesion, (b) distant lesion, and (c) intratumor lesion, with or without trastuzumab therapy.